![Arsenal Biosciences co-founder and CEO Ken Drazan, MD](https://westlakebio.com/wp-content/uploads/2021/01/ken.jpg)
Programmable cell therapy company Arsenal Biosciences, which Westlake Village BioPartners seeded and significantly contributed to its Series A financing, today announced a $70 million multi-program discovery collaboration with Bristol Myers Squibb to advance next-generation T cell therapies for solid tumors.
For more information, please see this press release.